search

Active clinical trials for "Carcinoma, Renal Cell"

Results 1461-1470 of 1644

Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting

CarcinomaRenal Cell

This study is a registry of renal cancer patients treated with Nexavar. It aims to evaluate the actual dosing of Nexavar in "real-life" setting vs. the prescribed dose.

Completed5 enrollment criteria

Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib...

CarcinomaRenal Cell

This is a global, multi-centre, long-term, prospective, observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated for the first time with pazopanib. The study is designed to enroll approximately 700-1000 patients in over the course of an enrollment period of approximately 18 months.There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 30 months or until premature discontinuation (i.e., due to death, withdrawal of consent, lost to follow-up or study termination).

Completed9 enrollment criteria

Sutent Rechallenge In mRCC Patients

Metastatic Renal Cell Carcinoma

Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.

Completed7 enrollment criteria

A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal...

Renal Cell CarcinomaCardiotoxicity2 more

While sunitinib can be very helpful to treat kidney cancer, these medications can also cause side effects, including heart damage. Studies performed in the past did not look at heart function in detail, so the investigators do not know what happens to the heart when people start sunitinib treatment. The aim of the study is to prospectively study acute effects of sunitinib on heart function, overall fitness and blood markers of heart disease.

Completed14 enrollment criteria

Follow-Up Study of Kidney Cancer Patients

Renal Cancer

Background: In Central Europe, mortality rates for kidney cancers are higher and survival rates are lower than in the United States and Western Europe overall. The Central and Eastern European Renal Cancer Case-Control Study (CEERCC), completed in 2002, offers an opportunity to identify determinants that predict 5-year survival among kidney cancer patients. Objectives: To assess disease recurrence and progression among former participants in the CEERCC. To investigate the effect of genetics, lifestyle factors, medical conditions, occupation and diet on the outcome of kidney cancer patients in Europe. Eligibility: Former participants or next-of-kin of former participants in the CEERCC study. Design: Participants or their next-of-kin are interviewed for 60 minutes and are requested permission to collect relevant information from their or their family member s hospital and cancer registry records.

Completed3 enrollment criteria

Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With...

Renal Cell Carcinoma

The Sutent® Observational Study is being proposed to assess the real-world usage patterns and effectiveness and tolerability of treatment of Indian patients with advanced renal cell cancer with Sutent®. Generation of such information is expected to aid everyday clinical decision-making by Indian doctors and will add to the body of generalizable evidence.

Completed3 enrollment criteria

Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers...

Clear Cell Renal CancerCirculating Tumor Cells3 more

Circulating tumor cells (CTCs) have prognostic value in several tumor types, and increasing evidence suggests that molecular characterization of CTCs can serve as a "liquid biopsy" to understand and address treatment resistance. The goal of this proposal is to demonstrate that CTCs can be accurately enumerated and characterized in metastatic clear cell renal cancer (CCRC) and can serve as prognostic/predictive biomarkers to improve treatment. The challenge surrounding CTC analysis in CCRC is that most CTC technologies (including the clinical gold-standard CellSearch®) depend in epithelial markers such as EpCAM that are expressed at low or heterogeneous levels in CCRC. Members of the research team have developed a novel CTC microfluidic technology that can effectively detect CTCs that are completely undetectable by CellSearch® because of very low EpCAM expression, as well as allowing for CTC recovery for downstream molecular characterization. The goal of this proposal is therefore to test the hypotheses that (1) The microfluidics CTC technology will have better sensitivity/specificity relative to the CellSearch in metastatic CCRC; and (2) Enumeration of CTCs in metastatic CCRC patients (n=66) will have prognostic value, while molecular characterization of CTCs for expression of biomarkers (VHL, VEGF, mTOR, HIF1/HIF2, AKT) related to CCRC etiology will be predictive of response/resistance to targeted therapies. Although CCRC is relatively uncommon, the lack of established adjuvant treatments and high cost of targeted therapies in the palliative setting makes the search for new prognostic/predictive biomarkers an important clinical goal.

Completed11 enrollment criteria

Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With...

Metastatic Renal Cell Carcinoma (mRCC)

This is an international, multi-centre, prospective (partly retrospective), observational study to evaluate treatment patterns and clinical outcomes in patients with advanced or metastatic RCC treated with sunitinib in first line and/or receiving axitinib in second line post sunitinib. The study is designed to enroll approximately 750 patients over the course of an enrollment period of approximately 36 months.

Completed7 enrollment criteria

Bevacizumab in Metastatic Renal Cancer

Renal Cell Cancer

This is a non-interventional, multicenter study to evaluate efficacy and safety of intravenous bevacizumab (Avastin) in combination with interferon alpha-2a immunotherapy for first-line treatment in participants with advanced and/or metastatic renal cell cancer (mRCC) in daily routine.

Completed3 enrollment criteria

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic...

Metastatic Clear Cell Renal Cell Carcinoma

The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma

Completed5 enrollment criteria
1...146147148...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs